Let's check the charts are MU pulls back to its breakout point.
Let's check the charts again as ADBE rises higher.
After another GME earnings blunder and change of players, I see the stock as this: pure speculation with a strong balance sheet. But I believe the company can find a way to the next level -- though it could get zapped before getting there.
The shares have been in an uptrend from 1985. Yep, 1985.
I'm eyeing this biotech name as the Nasdaq 100 moves up -- again -- and small calls slip.
Investors seem to be taking a fresh interest in the company. Is this going to be a flash in the pan or the real deal?
The potential for a correction appears to be on the rise.
Do not ignore the new high in the advertising and marketing giant.
Here's why this currently under-the-radar med-tech stock could pump higher soon.
The charts of the biopharmaceutical company are telling a largely bullish story.